Saniona AB (publ) (STO:SANION)

Sweden flag Sweden · Delayed Price · Currency is SEK
19.60
-0.12 (-0.61%)
At close: Dec 5, 2025
185.30%
Market Cap 2.71B
Revenue (ttm) 743.21M
Net Income (ttm) 573.47M
Shares Out 138.03M
EPS (ttm) 4.56
PE Ratio 4.30
Forward PE 8.71
Dividend n/a
Ex-Dividend Date n/a
Volume 1,450,837
Average Volume 1,244,917
Open 19.36
Previous Close 19.72
Day's Range 19.20 - 20.15
52-Week Range 5.41 - 20.10
Beta 1.20
RSI 71.33
Earnings Date Nov 27, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 22
Stock Exchange Nasdaq Stockholm
Ticker Symbol SANION
Full Company Profile

Financial Performance

Financial Statements

News

Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...

Saniona AB (FRA:30S) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Strength Propel Growth

1 day ago - GuruFocus

Q3 2025 Saniona AB Earnings Call Transcript

Q3 2025 Saniona AB Earnings Call Transcript

1 day ago - GuruFocus